The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) is a huge mover today! About 193,532 shares traded hands. Regulus Therapeutics Inc (NASDAQ:RGLS) has declined 73.10% since April 6, 2016 and is downtrending. It has underperformed by 75.06% the S&P500.
The move comes after 8 months negative chart setup for the $112.66M company. It was reported on Nov, 8 by Barchart.com. We have $1.91 PT which if reached, will make NASDAQ:RGLS worth $13.52 million less.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Wednesday, November 2 the stock rating was maintained by Needham with “Buy”. The firm earned “Buy” rating on Tuesday, June 28 by Needham. The company was maintained on Tuesday, June 28 by Chardan Capital Markets. On Wednesday, April 13 the stock rating was initiated by Chardan Capital Markets with “Buy”. The rating was maintained by Wedbush with “Buy” on Wednesday, August 5. BMO Capital Markets downgraded the shares of RGLS in a report on Tuesday, June 28 to “Market Perform” rating. The stock has “Outperform” rating given by BMO Capital Markets on Tuesday, April 12. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, June 7.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.19, from 1.04 in 2016Q1. The ratio improved, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
Mufg Americas reported 1,155 shares or 0% of all its holdings. Macquarie Gru accumulated 50,000 shares or 0% of the stock. Sabby Lc accumulated 49,231 shares or 0.01% of the stock. Bank & Trust Of America Corporation De last reported 0% of its portfolio in the stock. Amici Capital Limited Liability Co last reported 0.04% of its portfolio in the stock. Alliancebernstein Lp last reported 47,100 shares in the company. Schwab Charles Investment Mngmt Incorporated holds 61,781 shares or 0% of its portfolio. Wellington Grp Limited Liability Partnership has invested 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS). Dafna Cap Management Ltd Llc last reported 421,500 shares in the company. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Regulus Therapeutics Inc (NASDAQ:RGLS) for 1,508 shares. Globeflex Cap L P last reported 0.06% of its portfolio in the stock. Oxford Asset Mgmt has 482,143 shares for 0.06% of their US portfolio. The New York-based Retail Bank Of New York Mellon Corp has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). Legal And General Group Public Limited Co accumulated 6,785 shares or 0% of the stock. Proshare Advsr Limited Liability holds 44,037 shares or 0% of its portfolio.
More news for Regulus Therapeutics Inc (NASDAQ:RGLS) were recently published by: Fool.com, which released: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” on June 28, 2016. Fool.com‘s article titled: “Why Regulus Therapeutics Inc. Fell 20.1% in April” and published on May 10, 2016 is yet another important article.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.